Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.41 |
| ▸ | NOS3 | P29474 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12120357 | 1.00 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3NOS3NOS1 | |
| Bromide SCHEMBL1306413 | 0.98 | SLC6A4 (0.40) | SLC6A4SLC6A2SLC6A3NOS3NOS1 | |
| SCHEMBL1307225 | 0.88 | NOS3 (0.35) | SLC6A4SLC6A2SLC6A3NOS3NOS1 | |
| SCHEMBL12120285 | 0.88 | SLC6A4 (0.43) | SLC6A4SLC6A2SLC6A3NOS3NOS1 | |
| SCHEMBL26197502 | 0.88 | SLC6A4 (0.43) | SLC6A4SLC6A2SLC6A3NOS3NOS1 | |
| Bromide SCHEMBL1307607 | 0.86 | SLC6A4 (0.42) | SLC6A4SLC6A2SLC6A3NOS3NOS1 | |
| SCHEMBL19292100 | 0.85 | SLC6A2 (0.45) | SLC6A4SLC6A2SLC6A3NOS3NOS1 | |
| SCHEMBL1307919 | 0.84 | ALDH1A1 (0.40) | SLC6A4SLC6A2SLC6A3NOS3NOS1 | |
| SCHEMBL28891294 | 0.83 | SLC6A4 (0.40) | SLC6A4SLC6A2SLC6A3NOS3NOS1 | |
| SCHEMBL28891291 | 0.83 | SLC6A4 (0.40) | SLC6A4SLC6A2SLC6A3NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014082889-A1 | NOVEL IMIDAZOLINES AS DUAL INHIBITORS OF MDM2 AND MDMX | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-05 | — | — | WO | disclosed |
| US-20140148443-A1 | Novel Imidazolines as dual inhibitors of MDM2 and MDMX | HOFFMANN-LA ROCHE INC. (US) | 2014-05-29 | — | — | US | disclosed |
| WO-2011106650-A2 | NOVEL P53-MDM2/P53-MDM4 ANTAGONISTS TO TREAT PROLIFERATIVE DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148443-A1 | Novel Imidazolines as dual inhibitors of MDM2 and MDMX | MDM2, MDM4, TP53 | SLC6A4 4537/4885SLC6A2 4796/4885SLC6A3 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.